Radiogenomics Consortium (RGC)


The Radiogenomics Consortium was established in November 2009. The scientific hypothesis underlying the development of the consortium is that a cancer patient's likelihood of developing toxicity to radiation therapy is influenced by common genetic variations, such as single nucleotide polymorphisms (SNPs).

The Consortium members undertake collaborative projects to identify SNPs associated with adverse effects following radiotherapy, share data and samples, perform meta-analyses, and work together to submit research grant applications.


The objectives of the Radiogenomics Consortium are to expand knowledge of the genetic basis for differences in radiosensitivity and to develop assays to help predict the susceptibility of cancer patients for the development of adverse effects resulting from radiotherapy, through:

Organizational Structure

A Coordinating Committee was established to run the Consortium. The lead coordinators for the Radiogenomics Consortium are Barry Rosenstein, Ph.D., of Icahn School of Medicine at Mount Sinai, New York, and Catharine West, Ph.D., of the University of Manchester, UK.

Other members of the Committee are:

The Committee also includes a representative from the NCI, Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N.

Lynda Rath of Icahn School of Medicine at Mount Sinai and Holly Summersgill, Ph.D., of the University of Manchester provide administrative support.


As of April 2019, membership of the Radiogenomics Consortium consists of 222 members in 33 countries across 133 institutions.

The Radiogenomics Consortium is open to all investigators interested in studying the relationship between genetic variation and radiation therapy toxicity.

Anyone interested in joining RGC should email Lynda Rath.

Funding Sources

Support for logistical needs of the Consortium has been provided by NCI's Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) and the Radiation Research Program (RRP) in the Division of Cancer Treatment and Diagnosis (DCTD). Many members of the RGC are principal or co-investigators for grants that support research in radiogenomics and receive funding from the National Cancer Institute, European Commission, Cancer Research UK, National Institute for Health Research, Canadian Institutes of Health, U.S. Department of Defense, Deustsche Krebshilfe e.V, Health Research Fund, National Science Centre, and Spanish Ministry of Health.












  • West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, Bentzen S, Burnet N, Chang-Claude J, Chuang E, Coles C, De Ruyck K, De Ruysscher D, Dunning A, Elliott R, Fachal L, Hall J, Haustermans K, Herskind C, Hoelscher T, Imai T, Iwakawa M, Jones D, Kulich C; EQUAL-ESTRO, Langendijk JH, O'Neils P, Ozsahin M, Parliament M, Polanski A, Rosenstein B, Seminara D, Symonds P, Talbot C, Thierens H, Vega A, West C, Yarnold J. Establishment of a Radiogenomics ConsortiumInt J Radiat Oncol Biol Phys. 2010 Apr;76(5):1295-6.
  • West C, Rosenstein BS. Establishment of a radiogenomics consortiumRadiother Oncol. 2010 Jan;94(1):117-8.


The 2019 Radiogenomics Meeting was held in June 2019 at The University of Rochester. Please check this website for details of future RGC meetings or send an email to Holly Summersgill for more information.


Lead Investigator(s)

NCI Contact